Vanguard Group Inc. Buys 1,706,837 Shares of Tempus AI, Inc. $TEM

Vanguard Group Inc. raised its stake in Tempus AI, Inc. (NASDAQ:TEM) by 22.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,441,607 shares of the company’s stock after acquiring an additional 1,706,837 shares during the period. Vanguard Group Inc. owned approximately 5.43% of Tempus AI worth $762,032,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Cranbrook Wealth Management LLC bought a new position in shares of Tempus AI in the third quarter worth $25,000. GAMMA Investing LLC bought a new position in Tempus AI in the 3rd quarter valued at about $28,000. Allworth Financial LP raised its position in shares of Tempus AI by 5,000.0% in the 2nd quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after buying an additional 450 shares in the last quarter. SouthState Corp boosted its position in shares of Tempus AI by 3,761.5% during the 2nd quarter. SouthState Corp now owns 502 shares of the company’s stock worth $32,000 after acquiring an additional 489 shares in the last quarter. Finally, Tsfg LLC increased its stake in Tempus AI by 1,515.2% in the third quarter. Tsfg LLC now owns 533 shares of the company’s stock valued at $43,000 after acquiring an additional 500 shares during the last quarter. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Trading Down 2.7%

Shares of Tempus AI stock opened at $58.37 on Monday. The stock has a market capitalization of $10.38 billion, a PE ratio of -49.05 and a beta of 5.22. Tempus AI, Inc. has a 52 week low of $36.22 and a 52 week high of $104.32. The stock has a 50 day moving average price of $62.35 and a two-hundred day moving average price of $73.62. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28.

Analysts Set New Price Targets

A number of research analysts have recently commented on TEM shares. Robert W. Baird assumed coverage on shares of Tempus AI in a report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. Piper Sandler lowered their price target on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th. HC Wainwright reduced their price objective on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Finally, Canaccord Genuity Group decreased their price objective on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, December 22nd. Eight investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $85.92.

Insider Transactions at Tempus AI

In related news, EVP Erik Phelps sold 9,464 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $59.43, for a total value of $562,445.52. Following the transaction, the executive vice president owned 79,816 shares of the company’s stock, valued at approximately $4,743,464.88. This trade represents a 10.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the stock in a transaction on Wednesday, January 28th. The shares were sold at an average price of $65.56, for a total value of $10,899,350.00. Following the completion of the sale, the chief executive officer directly owned 8,941,533 shares of the company’s stock, valued at $586,206,903.48. The trade was a 1.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 596,035 shares of company stock valued at $37,505,125. Corporate insiders own 26.27% of the company’s stock.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.